Is NCT06592924 recruiting in Phoenix, AZ?

Yes, NCT06592924 is currently recruiting participants at its Phoenix, AZ location. This prostate cancer (adenocarcinoma) clinical trial is actively enrolling qualified participants.

How do I join the prostate cancer (adenocarcinoma) clinical trial in Phoenix?

To join this clinical trial in Phoenix, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Phoenix clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Prostate Cancer (Adenocarcinoma) Clinical Trial in Phoenix, AZ

About This Prostate Cancer (Adenocarcinoma) Study in Phoenix

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).

Sponsor: Canadian Cancer Trials Group

Who Can Participate

Inclusion Criteria

Histologically/cytologically confirmed adenocarcinoma of the prostate or participants with a PSA \>100 ng/ml (100 ug/L) and radiographic evidence of metastatic disease at diagnosis.

Metastatic disease by conventional imaging (bone scan or CT and/or MRI or PSMA-PET scan at the time of ADT initiation.

PSA of ≥ 2.0 ng/ml (2.0 ug/L) prior to commencement of ADT (this refers to patients who have histologically/cytologically confirmed adenocarcinoma of the prostate)

Patients will have recovered from any treatment-related toxicities prior to enrollment (unless ≤ grade 1, irreversible, or considered by investigator as not clinically significant).

Patients may enroll with persistent toxicities attributable to ADT, including hot flushes and fatigue, of any grade, provided these toxicities are clinically stable, not rapidly worsening, and not considered by the Investigator to pose a safety risk or impair the patient's ability to comply with study procedures. Such toxicities do not need to resolve to Grade ≤1 prior to study entry.

Receipt of ADT for mCSPC for at least 6 months and no greater than 12 months (+/- 3 weeks) at time of enrollment.

Receipt of ARPI (e.g. abiraterone acetate, enzalutamide, apalutamide, or darolutamide) for at least 4 months (+/- 2 weeks) at time of enrollment

Patients may have had radiotherapy to prostatic bed and/or metastatic sites prior to enrollment. Potential trial participants should have recovered from radiotherapy-related toxicities prior to enrollment.

Serum testosterone \<1.7 nmol/L or 50 ng/dL.

PSA ≥ 0.2 ng/ml (0.2 ug/L) within 28 days of enrollment.

Candidate for docetaxel chemotherapy

ECOG Performance Status (PS) 0 to 2.

Adequate organ and marrow function measured within 28 days prior to enrollment.

Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrollment in the trial to document their willingness to participate.

Participants must be accessible for treatment and follow-up. Investigators must assure themselves the participants enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.

In accordance with CCTG policy, protocol treatment is to begin within 10 working days of participant enrollment.

If the participant and the participant's partner are of childbearing potential, they must agree to use medically accepted methods of contraception

HIV-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

Participant access to all protocol therapies must be confirmed prior to enrollment

Exclusion Criteria

Confirmed PSA progression, defined by an increase in PSA of 25% above the nadir since achieving castration on ADT, an absolute increase in PSA value of 2.0 ng/ml (ug/L) above nadir, and a subsequent increase in PSA of 25% further separated by 3 or more weeks.

Evidence of confirmed radiographic progression or clinical progression since start of ADT. Participants may be enrolled on the study if, in the opinion of the investigator, any new bone lesions on bone scan and CT represent flare or treatment effect.

Docetaxel criteria:

Prior treatment with taxane chemotherapy

Grade 2 or worse peripheral neuropathy

Severe hypersensitivity to drugs formulated with polysorbate 80

Clinically significant cardiac disease including:

History of unstable angina pectoris, symptomatic pericarditis, or myocardial infarction within 6 months prior to study entry.

History of documented congestive heart failure (New York Heart Association functions classification III-IV).

Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make this protocol unreasonably hazardous.

Patients with a prior or concurrent malignancy whose natural history of treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Concurrent treatment with other anti-cancer systemic therapy other than ADT and ARPI.

Live attenuated vaccination administered within 30 days prior to enrollment/randomization.

For participants with a history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.

Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

High-grade neuroendocrine prostate cancer or small cell features (except if a participant has no histological diagnosis but a PSA \>100 ng/ml (\>100 ug/L) at diagnosis and radiographic evidence of metastatic disease)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT06592924) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prostate Cancer (Adenocarcinoma) Treatment Options in Phoenix, AZ

If you're searching for prostate cancer (adenocarcinoma) treatment options in Phoenix, AZ, this clinical trial (NCT06592924) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer (adenocarcinoma) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prostate cancer (adenocarcinoma) clinical trials near you to find additional studies recruiting in your area.

Prostate Cancer (Adenocarcinoma) Clinical Trial in Phoenix, AZ

Expert Care in Phoenix

IRB Approved

No-Cost Care

Apply for This Phoenix Location

Why Participate?

Simple Process